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doi:10.1016/j.jtcvs.2005.11.018bjective: We sought to evaluate magnesium as a neuroprotectant in patients
ndergoing cardiac surgery with cardiopulmonary bypass.
ethods: From February 2002 to September 2003, 350 patients undergoing elective
oronary artery bypass grafting, valve surgery, or both were enrolled in a random-
zed, blinded, placebo-controlled trial to receive either magnesium sulfate to in-
rease plasma levels 1½ to 2 times normal during cardiopulmonary bypass (n 
74) or no intervention (n  176). Neurologic function, neuropsychologic function,
nd depression were assessed preoperatively, at 24 and 96 hours after extubation
neurologic) and at 3 months (neuropsychologic, depression). Neurologic scores
ere analyzed using ordinal longitudinal methods, and neuropsychologic and
epression inventory data were summarized by principal component analysis,
ollowed by linear regression analysis using component scores as response
ariables.
esults: Seven (2%) patients had a postoperative stroke, 2 (1%) in the magnesium
nd 5 (3%) in the placebo group (P  .4). Neurologic score was worse postoper-
tively in both groups (P  .0001); however, magnesium group patients performed
etter than placebo group patients (P  .0001), who had prolonged declines in
hort-term memory and reemergence of primitive reflexes. Three-month neuropsy-
hologic performance and depression inventory score were generally better than
reoperatively, with few differences between groups (P  .6); however, older age
P  .0006), previous stroke (P  .003), and lower education level (P  .0007)
ere associated with worse performance.
onclusions: Magnesium administration is safe and improves short-term postoper-
tive neurologic function after cardiac surgery, particularly in preserving short-term
emory and cortical control over brainstem functions. However, by 3 months, other
actors and not administration of magnesium influence neuropsychologic and de-
ression inventory performance.
eurologic and neuropsychologic dysfunction are major causes of mortality
and morbidity after cardiac surgery1,2 and are associated with prolonged
hospital stay and use of intermediate- or long-term care facilities.3 Neuro-sychologic dysfunction is evident in 50% to 80% of patients at hospital discharge,
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CD0% to 50% at 6 weeks, and 10% to 30% at 6 months
ostoperatively4-7; thus, early neuropsychologic dysfunc-
ion is implicated in late cognitive deterioration.8
Although measures to prevent brain injury have been
tudied,9,10 strategies to minimize injury, as advocated for
troke victims,11 have received less attention. After an isch-
mic neurologic insult, glutamate is released, activating
-methyl-D-aspartate (NMDA), leading to increased so-
ium and calcium ion conduction across cell membranes
nd exacerbation of neurologic injury. Magnesium sulfate, a
oncompetitive NMDA antagonist with clinical benefit in
cute stroke,11 has not been investigated as a neuropro-
ectant in cardiac surgery. Therefore, we conducted a single-
nstitution randomized clinical trial to determine whether
ncreased magnesium during cardiac surgery and in the first
4 hours postoperatively is neuroprotective.
atients and Methods
tudy Design
rom February 2002 to September 2003, 350 patients (mean age
4  12 years) undergoing elective on-pump coronary artery
ypass grafting (CABG), valve surgery, or combined CABG and
alve surgery were enrolled in a randomized, blinded, placebo-
ontrolled clinical trial at Cleveland Clinic to receive either mag-
esium to increase plasma levels to between 3.6 and 4.8 mg · dL1
uring the operation and for 24 hours thereafter (magnesium
roup, n  174)12-14 or no intervention (placebo group, n  176;
ppendix E1). Patients with preoperative atrial fibrillation or renal
mpairment were excluded (Figure E1). Patients were randomized
:1 at operation, with a block size of 2 and 4, independently for
ach of 11 operating rooms. Preoperative and operative character-
stics of the 2 groups were well balanced (Table 1). The Pharmacy
epartment (J.P.) prepared study medications, the anesthetic team
dministered the 24-hour infusion, and the perfusion teams dosed
he cardiopulmonary bypass (CPB) circuit. All were blinded to the
tudy except perfusion teams, who were required to monitor and
aintain magnesium levels during CPB.
This study was approved by the institutional review board, and
atients provided written informed consent.
agnesium Dosing
atients randomized to the magnesium group received 780 mg (32
mol) of MgSO4 in 100 mL of normal saline intravenously over
5 minutes during anesthesia induction, followed by 3160 mg
130 mmol) in 100 mL of normal saline over 24 hours; the CPB
ircuit was primed with MgSO4 to a concentration of 3.6
g · dL1. The plasma magnesium level was measured every 15
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CPB  cardiopulmonary bypass
NMDA N-methyl-D-aspartate
WPNS Western Perioperative Neurologic Scaleinutes during CPB. If it decreased to less than 3.6 mg · dL1,
54 The Journal of Thoracic and Cardiovascular Surgery ● AprigSO4 was administered to achieve levels between 3.6 and 4.8
g · dL1 (Figure 1).
Patients randomized to the placebo group received normal
aline intravenously in the CPB circuit and over 24 hours in bags
nd syringes indistinguishable from those used for the magnesium
roup.
onduct of Operations
nesthesia was induced intravenously with a combination of mi-
azolam, 3 to 5 mg; fentanyl, up to 0.25 mg; and sodium thiopen-
al, 3 to 5 mg · kg1 (in patients with mitral or aortic valve stenosis
r left ventricular ejection fraction 30%, etomidate, 0.3-0.5
g · kg1, was used instead of sodium thiopental). It was main-
ained with inhaled isoflurane, 1% to 2%, supplemented with
entanyl up to 1 mg.
CPB was instituted with a conventional roller-pump system and
acuum-assisted venous return15 using a heparin-coated circuit
hat included a 25-m arterial filter. Arterial flow rate was 2.0 to
.4 L · min1 · m2, with mean arterial pressure maintained be-
ween 50 and 70 mm Hg. Body temperature was either kept at
7°C or allowed to drift to 32°C to 34°C. Blood-gas management
as by alpha-stat strategy.
ssessments
Safety. Postoperative mortality and morbidity data were col-
ected by research nurses and entered into the Cardiovascular
nformation Registry concurrently with patient care. This reg-
stry is approved for use in research by the institutional review
oard.
Neurologic assessment. The Western Perioperative Neuro-
ogic Scale (WPNS)16 was used to assess neurologic performance
reoperatively and at 24 and 96 hours after extubation. Fourteen
ests were performed by an individual certified to administer them
S.K.B.) and were grouped into 4 domains:
● Mentation (4 tests): level of consciousness; orientation to
time, place, and person; short-term memory; and speech
● Motor function (5 tests): motor strength in right and left
upper and lower limbs, cranial nerves (facial motor func-
tion)
● Sensory (4 tests): sensation in right and left upper and lower
limbs
● Cerebellar function (4 tests): movement, gait, reflexes, prim-
itive reflexes (glabellar tap, snout response, suck response,
palmomental reflex, grasp reflex). For clinical reasons, gait
was not assessed 24 hours after extubation.
Neuropsychologic and depression assessment. A neuropsy-
hologic assessment battery and depression inventory were admin-
stered by a neuropsychologist (R.I.N.) or neuropsychology tech-
ician (E.W.) preoperatively and 3 months postoperatively. Tests
ncluded the following:
● Hopkins Verbal Learning Test (HVLT; total, discrimination
index, and delayed recall) to measure memory
● Controlled Oral Word Association Test (COWAT) and Bos-
ton Naming Test (BNT) to measure word fluency and con-
frontation naming
● Digit Symbol and Symbol Search, subtests of the Wechsler
Adult Intelligence Scale, third edition, to produce the Pro-
l 2006
T
C
D
E
P
C
N
P
S
S
i
c
‡
p
Bhudia et al Surgery for Acquired Cardiovascular Disease
A
CDABLE 1. Patient characteristics and procedure details
haracteristic Magnesium group (n  174), No. (%) Placebo group (n  176), No. (%) P value
emography
Female 41 (24) 39 (22) .8
Age (y), mean  SD 64  12 64 13 .7
Body mass index (kg · m2) 29  5 30 6 .4
ducation
Years 14 3 14 3 .3
WRAT-3 reading score
Raw 46 6 47 6 .5
Grade level 10.4 2.9 10.5 2.8 .6
Standardized (Z) score* 0.8, 0.2, 0.87 0.86, 0.2, 0.87 .9
reoperative neurologic morbidity
CVA 1 (0.6) 5 (3) .2†
TIA 10 (6) 10 (6) .9
Syncope 13 (7) 12 (7) .8
ardiac morbidity
Previous MI 69 (40) 62 (35) .4
Atrial fibrillation 4 (2) 3 (2) .7†
Previous cardiac operation 35 (20) 33 (19) .7
NYHA class .07
I 44 (25) 42 (24)
II 101 (58) 118 (67)
III 22 (13) 15 (9)
IV 7 (4) 1 (0.6)
Aortic regurgitation (moderate or greater) 50 (29) 38 (22) .1
Aortic stenosis (moderate or greater)‡ 36 (21) 57 (34) .01
Mitral regurgitation (moderate or greater)§ 68 (40) 73 (42) .7
Mitral stenosis (moderate or greater) 2 (1.1) 5 (3) .4†
Coronary disease
LMT stenosis (50%)¶ 23 (14) 27 (16) .6
LAD stenosis (70%)# 89 (53) 87 (51) .7
LCx stenosis (70%)# 77 (46) 63 (37) .09
RCA stenosis (70%)¶ 79 (48) 84 (49) .7
Three-system disease 77 (46) 67 (39) .2
oncardiac comorbidity
Hypertension 120 (69) 126 (72) .5
Diabetes mellitus 37 (21) 39 (22) .8
Peripheral vascular disease 77 (44) 59 (34) .04
Carotid disease 69 (40) 54 (31) .08
COPD 30 (17) 23 (13) .3
History of smoking 93 (53) 92 (53) .9
rocedure
Isolated CABG 71 (41) 57 (32) .1
CABG  valve procedure 44 (25) 54 (31) .3
Aortic valve repair 5 (3) 2 (1) .3†
Aortic valve replacement 56 (32) 74 (42) .06
Mitral valve repair 44 (25) 45 (26) 1
Mitral valve replacement 8 (5) 12 (7) .4
Tricuspid valve repair 4 (2) 6 (3) .8†
upport
Perfusion time (min) 92 35 93 36 .8
Ischemic time (min) 74 28 74 31 .9
D, Standard deviation; WRAT-3, Wide Range Achievement Test, third edition; CVA, cerebrovascular accident; TIA, transient ischemic attack; MI, myocardial
nfarction; NYHA, New York Heart Association; LMT, left main trunk; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right
oronary artery; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting. *15th, 50th, and 85th percentiles. †Fisher’s exact test.
Six unknown in each group. §Two unknown in magnesium group, 1 unknown in placebo group. Three unknown in magnesium group, 4 unknown in
lacebo group. ¶Eight unknown in magnesium group, 6 unknown in placebo group. #Seven unknown in magnesium group, 6 unknown in placebo group.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 4 855
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A
CDcessing Speed Index, and Trail-Making Test (Forms A and
B) to measure timed visual-motor speed
● Grooved Pegboard (for dominant and nondominant hand) to
measure timed manual dexterity
● Beck Depression Inventory, second edition, to measure de-
pressive symptomatology.
Level of education and intelligence were determined preoper-
tively by total completed years of education and reading ability,
s assessed by the Wide Range Achievement Test (WRAT, third
dition).
Two hundred seventy-three (78%) patients completed the
-month neuropsychologic reassessment (the study was powered
or 300 patients). Patient and procedure variables of those who
ere assessed were well balanced between the magnesium and
lacebo groups (Table E1), but those who refused reassessment
ere more likely to be female or to have had noncardiac surgery
uring follow-up (Table E2). Five (1%) patients died before
eassessment.
ata Analysis
ll analyses were performed with SAS statistical software (version
.2; SAS Institute, Inc, Cary, NC).
Neurologic assessment. Longitudinal ordinal logistic regres-
ion was used to analyze 24- and 96-hour WPNS scores, with
reoperative score, randomization group, and time of testing
orced into the model as previously described.17 Only a few
atients had low scores, and therefore scores were collapsed
nto 3 categories to meet the proportional odds assumption of
he model.
Neuropsychologic assessment. Twelve test scores (Digit Sym-
ol and Symbol Search were used instead of the Processing Speed
ndex) were available for analysis at both preoperative and post-
perative assessment. WRAT-3 reading score, preoperative scores,
nd randomization group, were included in all analyses.
Because neuropsychologic tests are somewhat correlated, we used
igure 1. Perioperative magnesium levels. Open circles (placebo
roup) and filled circles (magnesium group) are mean values
ithin different time intervals. Solid lines are evolution of pre-
icted mean values over time for each group.rincipal component analysis to condense the information into a few a
56 The Journal of Thoracic and Cardiovascular Surgery ● Aprincorrelated variables (components), one of which was the depression
nventory by itself, with minimal loss of information.18 We applied
his technique (PROC PRINCOM, SAS) to preoperative test scores of
ll 350 patients, identifying 4 principal components that accounted for
2% of total variation (Table E3), and used the component coeffi-
ients to calculate preoperative component scores and those at
-month follow-up. We then performed multivariable linear regres-
ion using component scores as response variables to assess the effect
f magnesium. All preoperative and intraoperative variables (Table 1)
ere considered in these analyses, along with interaction between age
nd randomization group.
Other variables. Plasma magnesium levels were measured
reoperatively, during CPB, at 2 to 6 AM on postoperative day 1,
nd at 24  6 hours. During CPB, blood flow, mean arterial
ressure, temperature, and hematocrit levels were recorded. Tem-
oral trends of these variables were similar for each group (P 
08). In addition, Cardiovascular Information Registry personnel
ollected preoperative, operative, and postoperative data concur-
ently with patient care.
Presentation. Continuous variables are presented as mean 
tandard deviation and as 15th, 50th (median), and 85th percentiles
hen values were skewed; comparisons were made using the
ilcoxon rank-sum test. Categorical data are described using
requencies and percentages; comparisons were made using the 2
est or Fisher’s exact test when the frequency was less than 5.
ctual and estimated percentages of patients with the highest
eurologic scores are presented with 68% confidence limits, equiv-
ABLE 2. Safety
ospital morbidity
Magnesium group
(n  174),
No. (%)
Placebo group
(n  176),
No. (%) P value
eturn to OR for
bleeding
4 (2) 3 (2) .7*
acked RBC transfusion
(units)
.6
0 108 (62) 118 (67)
1 16 (9) 16 (9)
2 23 (13) 14 (8)
3 11 (6) 11 (6)
4 7 (4) 8 (5)
5 9 (5) 9 (5)
yocardial infarction 0 (0) 1 (0.6) 1*
enal insufficiency 0 (0) 0 (0)
espiratory insufficiency 5 (3) 3 (2) .5*
epticemia 3 (2) 4 (2) 1*
trial fibrillation 57 (33) 64 (36) .5
ength of stay (d)
ICU† 1, 2, 3 1, 2, 3 .9
Postoperative† 5, 6, 9 5, 6, 9 .9
Hospital† 5, 7, 11 5, 7, 10 .3
R, Operating room; RBC, red blood cells (includes both intraoperative and
ostoperative transfusions); ICU, intensive care unit. *Fisher’s exact test.
15th, 50th, and 85th percentiles.lent to 1 standard error.
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A
CDesults
afety
here were 2 (1%) hospital deaths, 1 in each group (P 1).
owever, 5 (1%) patients died within their 3-month enroll-
ent, none from stroke or neurologic injury. Mortality was
imilar in the magnesium (1 death) and placebo (4 deaths)
roups (P[log rank]  .2), as were other in-hospital morbid-
ties, including transfusion requirements (Table 2). Length of
ntensive care unit, postoperative, and total hospital stays
ere similar.
eurologic Assessment
even (2%) patients had a postoperative cerebrovascular
ccident, 2 (1%) in the magnesium group and 5 (3%) in the
lacebo group (P[log rank]  .3). Preoperative WPNS
cores were similar in both groups (Figure 2).
WPNS scores decreased by 24 hours postoperatively in
oth groups (P .0001); by 96 hours, the magnesium group
ad recovered nearly to preoperative performance, but the
lacebo group had not (P  .003). Thus, neurologic decline
r death from neurologic injury (which did not occur within
months in either group), the study’s composite primary
nd point, was less at 96 hours in the magnesium group than
he placebo group (P  .01).
Other factors associated with improved WPNS were
igher preoperative score, younger age, and shorter isch-
mic time (Table 3).
Of the WPNS domains, sensory and motor functions
ppeared to be relatively unaffected in the magnesium (P 
3) and placebo (P  .07) groups. The mentation score
consciousness, orientation, short-term memory, and
peech) decreased in both groups by 24 hours (P  .0005);
y 96 hours, it had returned to preoperative levels (P  .1)
n the magnesium group but remained depressed in the
TABLE 3. Factors associated with better neurologic per-
formance (higher Western Perioperative Neurologic Scale
Scores)*
Factor Coefficient  SD P value
Magnesium group 1.6 0.42 .0001
Higher preoperative score 3.0 0.40 .0001
Time† 2.5  4.5 .5
Time and magnesium group† 21  10 .04
Younger‡ 0.51 0.19 .007
Shorter myocardial ischemic time§ 0.79 0.42 .06
Lower bilirubin 0.36 0.20 .07
Lower BUN 0.81 0.46 .08
SD, Standard deviation; BUN, blood urea nitrogen. *Higher score is
better. †(1/time), inverse transformation, where time is the interval
between 24- and 96-hour assessments. ‡Exp(age/50), exponential trans-
formation. §Ln(myocardial ischemic time), logarithmic transformation.
Ln(BUN), logarithmic transformation.igure 2. Overall and domain scores of the Western Perioperative
eurologic Scale preoperatively and at 24 and 96 hours after
xtubation in the magnesium (filled circles) and placebo (open
ircles) groups. Shown are percentages of patients reaching the
aximum overall and domain scores (scores indicated on verti-
al axes). Unadjusted percentages with 68% confidence bars are
iven for patients with complete scores. A, All 16 neurologic
ests. B, Mentation (5 tests). C, Motor (4 tests). D, Sensory function
4 tests). E, Cerebellar function (3 tests).lacebo group. Cerebellar function (movement, gait, re-
and Cardiovascular Surgery ● Volume 131, Number 4 857
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A
CDexes, and primitive reflexes) remained at preoperative lev-
ls in the magnesium group (P  .5), but decreased in the
lacebo group by 24 hours and was not restored by 96 hours
P  .002); the difference between groups was unlikely to
e due to chance (P .003). Decrease in cerebellar function
core was mainly due to reappearance of primitive reflexes,
uch as snout and suck responses and grasp reflexes (see the
ethods section). The older the patient in the magnesium
roup, the better the cerebellar function score; in contrast,
he older the patient in the placebo group, the worse the
core (Figure 3 and Table 4).
europsychologic and Depression Assessment
europsychologic scores in multiple domains and depres-
ion inventory scores were generally somewhat better 3
onths postoperatively than preoperatively because of fa-
iliarity with test procedures during retesting (Figure E2
nd Table E4), and changes were similar between groups
P .6). However, older patients (P .006) and those with
revious stroke (P .003), extensive coronary disease (P
02), or lower education level (P  .0007) performed worse
t 3-month follow-up than preoperatively (Tables E5-E8).
iscussion
here is great interest in developing strategies to prevent
eurologic dysfunction in patients undergoing cardiac sur-
ery.1,2,19-21 However, rather than focusing on prevention of
eurologic insult, this study addresses the issue of minimiz-
ng injury from such insults. To our knowledge, magnesium
as not been used previously as a neuroprotectant in cardiac
igure 3. Estimated percentage of patients with total cerebellar
unction score of 9 (best possible score) as a function of age. The
omogram represents a solution of the multivariable equation in
able 4 (date of operation set to June 2003). Dashed lines are
stimated 68% confidence intervals.urgery. The rationale for its use is that neuronal damage o
58 The Journal of Thoracic and Cardiovascular Surgery ● Aprifter injury is attributable to release of glutamate from
eurons and glia,22 and magnesium is a noncompetitive
MDA receptor antagonist.23 Glutamate receptor modula-
ion has shown promise in animal and clinical studies.
emacemide, an NMDA antagonist, reduced neuropsycho-
ogic dysfunction after cardiac surgery but at the cost of
mportant side effects (ataxia, dizziness, drowsiness, fa-
igue, headache, nausea, and abdominal pain).24 Magnesium
hows no such toxicity. In addition, magnesium modulates
he ischemic brain injury cascade at other levels. These
nclude abilities to inhibit neurotransmitter release23 and
erebral vasospasm,25 antagonize voltage-gated calcium ion
hannels,26 and attenuate production of reactive oxygen
pecies.27
During CPB, serum magnesium levels might be de-
leted, and hypomagnesemia can persist for 24 hours post-
peratively.28 In animal models, brain magnesium defi-
iency before injury exacerbates functional deficits,29 and
imiting postinjury magnesium decline attenuates functional
eficit after brain injury.30 The level of serum magnesium
equired for neuroprotection is not well established, but
nimal studies indicate that a concentration of 3.62
g · dL1 reduces histologic infarct volume in ischemic
rain injury.12 In acute stroke, increasing serum magnesium
evels to 1½ to 2 times normal is beneficial.11
ey Findings
Safety. No adverse effects of elevated magnesium levels
ere observed in this study.
Neurologic assessment. The primary end point of the
tudy was achieved, with the better overall neurologic func-
ion in the magnesium group unlikely to be due to chance.
nterestingly, the WPNS demonstrated that magnesium re-
uced cerebellar complications, especially return of primi-
ive reflexes. After perioperative stroke or subtle brain in-
ury, these primitive reflexes reappear in up to 39% of
atients.4 Their reappearance is considered a sensitive marker
ABLE 4. Factors associated with better cerebellar func-
ion score
actor Coefficient  SD P value
agnesium group 3.5  1.7 .04*
igher preoperative cerebellar score 2.4 0.83 .003
ime† 0.00001 0.0013 .9
lder age in magnesium group‡ 1.1 0.51 .04
ounger age in placebo group§ 0.54 0.27 .04
ore recent date of operation 0.21 0.12 .07
D, Standard deviation. *Because of interaction terms, this value does not
epresent group difference. Rather, the difference is age related (Figure 3).
Interval between 24- and 96-hour assessments. ‡Interaction: magnesium
roup · exp(age/50). §Interaction: placebo group · exp(age/50). [1/(interval
rom 1/1/2002 to date of operation)], inverse transformation.T
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A
CDmmunodeficiency disease,32 neuropsychiatric disorders,33
lzheimer disease (where it is a poor prognostic sign),34,35
nd after cardiac surgery,4,36 particularly in the elderly.37
he phenomenon is complex and perhaps best interpreted
s nonspecific loss of cortical control over brainstem
unctions.38
Mentation, which includes short-term memory, was bet-
er preserved in patients receiving magnesium, with older
atients benefiting more than younger ones. This might
eflect greater brain reserve in younger patients.
We hypothesize, without supporting data, that rehabili-
ation of cardiac surgical patients might be enhanced if these
ubtle but sensitive and important deficits are reduced.
Neuropsychologic and depression assessment. Magne-
ium did not influence neuropsychologic function or depres-
ive symptomatology 3 months postoperatively, but other
ystemic factors, including older age, did. Neuropyscho-
ogic dysfunction and depression after cardiac surgery are
ighly variable. Timing of assessment is crucial, with more
ariability in dysfunction observed early after surgery. In
his study, neuropsychologic performance was generally
etter at 3 months than preoperatively, probably a manifes-
ation of the test–retest phenomenon.39
imitations
ypical of randomized clinical studies, only a small fraction
f this center’s cardiac surgical population was included
Figure E1), which might introduce bias. A major deterrent
o participation was need to return for 3-month follow-up
europsychologic and depressive symptom testing. Also,
ecause pretesting was required, patients undergoing emer-
ency and urgent operations were not included; such pa-
ients are particularly vulnerable to neurologic injury. Rec-
gnizing this limitation, we designed the study to include
ot only patients undergoing CABG, as has been the case in
ost studies of neurologic injury after cardiac surgery,3-8
ut also patients undergoing heart valve surgery, in whom
pportunity for neurologic injury from particulate matter
ight be even greater. CABG and valve surgery account for
he majority of cardiac operations performed.
Another limitation is that neuropsychologic assessment
as made only at 3 months and not earlier (when it is less
table) or longitudinally over years.8 Despite prior agree-
ent, a substantial number of patients refused postoper-
tive neuropsychologic testing, which could introduce
ias (Table E2). Neurologic assessment was made by using
formal, sensitive, and validated instrument.16 However,
eurologic assessment was not performed 3 months postop-
ratively. Thus, we do not know whether patients who
anifested neurologic abnormalities before hospital dis-
harge improved.
Finally, the study was designed to discover a possiblehort-term neuroprotective effect of magnesium elevation.
The Journal of Thoracict was not designed to assess duration of the effect or effects
n convalescence or long-term outcomes.
onclusions
ncreasing serum magnesium levels during CPB and for 24
ours thereafter is safe. It offers short-term neurologic benefits,
articularly in preserving short-term memory and preventing
eemergence of primitive reflexes. However, patient factors
rimarily influenced 3-month neuropsychologic function and
epressive symptomatology, not use of magnesium.
The trial suggests that future research be directed toward
scertaining duration of detectable neurologic benefit and
etermining whether the observed short-term benefits of
levated magnesium levels translate into helping patients
ecover more quickly and completely after cardiac surgery
r confer long-term neurologic benefit.
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iscussion
r Ralph J. Damiano (St Louis, Mo). Congratulations on a
eautifully designed, prospective randomized study. Studies like
his are sorely needed in our specialty to allow us, as surgeons, to
ptimize patient management. And I congratulate you on under-
aking a prospective study in what has become an even more
ifficult and perhaps confusing area.
I have a number of questions for you, and I will ask them one
t a time to give you a chance to respond.
First of all, why do you think the principal effect of magnesium
as on cerebellar function? It had very little effect certainly on
otor and sensory function, and even its effect on mentation was
ot dramatic. Is this due to some anatomic variability in the
istribution of NMDA receptors? How do you explain that from a
echanistic standpoint?
Dr Bhudia. Thank you, Dr Damiano. I think the main effect of
agnesium was to minimize any insult. If one was to experience
ny motor dysfunction, then the likelihood of a huge brain insult,
s in stroke, is high. It is similar for the sensory function.
What we are picking up in the cerebellar dysfunction are subtle
hanges, for example the primitive reflexes. This cerebellar dysfunc-
ion was more obvious in those receiving the placebo. These subtle
hanges are not obvious if we do not look for them. We believe that
he magnesium helps reduce the effect of these small insults to the
rain rather than the larger insults, which manifest as stroke.
One of the possible mechanisms for magnesium as a neuropro-
ectant is through its antagonist property on the NMDA receptor.
he distribution of NMDA receptors is different across the brain,
ut I do not think the reason for reduction in cerebellar dysfunction
s related to the NMDA receptor distribution.
Dr Damiano. Is there any clinical relevance to your findings?
ecause there were no changes between the groups at 3 months,
oes the small difference in cerebellar function have any real effect
n terms of patient recovery?
As a second part of this question, in your manuscript you sug-
ested that the early benefits of magnesium on cerebellar function
ight accelerate patient recovery, yet length of stay in this random-
zed study was exactly the same. Were there any objective measures
f accelerated recovery in the magnesium group?
Dr Bhudia. As for the short-term benefit, although the differ-
nce was mainly in the primitive reflexes, short-term memory was
lso better in those receiving magnesium. We therefore argue that
lthough the length of stay of patients was similar in both groups,
hese subtle changes can influence other factors. If short-term
emory is better, then getting back to routine tasks and going back
o work might occur sooner, even though at 3 months we did not
ee any difference between the 2 groups.
Dr Damiano. But is that something you are supposing and
ave no objective data to support?Dr Bhudia. No, we did not have any objective data to support it.
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Bhudia et al Surgery for Acquired Cardiovascular DiseaseDr Damiano. Also it might be of interest to the audience to
oint out that you are looking at fairly subtle differences in
eurocognitive testing.
Dr Bhudia. That’s right.
Dr Damiano. And even though there is a difference in cere-
ellar function, did you notice a difference in gait in these patients
r anything objective that would make that subtle difference ac-
ually have a clinical effect?
Dr Bhudia. The testing of cerebellar function, and all the other
odalities, was very objective. Although the changes might be
ubtle, they could make a difference to the overall well-being of
he patient.
Dr Damiano. There certainly is a lot of literature that says that
agnesium prevents atrial fibrillation, yet in your study you men-
ioned that there was no difference in atrial fibrillation between
roups. How do you explain how this finding relates to the rest of
he literature, which is fairly supportive that magnesium adminis-
ration prevents atrial fibrillation?
Dr Bhudia. We were puzzled about this as well. Patients in the
agnesium group had a similar incidence of atrial fibrillation as
hose in the placebo group, although this was not what we set out
o look for as the primary outcome. Also, other postoperative
utcomes, such as incidence of bleeding, infection, renal impair-
ent, and respiratory insufficiency, were similar in the 2 groups,
mplying that it was safe to give magnesium at these higher levels.
One speculation as to why magnesium did not reduce the
ncidence of atrial fibrillation is that the highest level of serumThe Journal of Thoracicould therefore distribute to the body, including the brain, and not
he myocardium.
Dr Damiano. Finally, just quickly, at the Cleveland Clinic, is
verybody receiving magnesium right now?
Dr Bhudia. That is the next step.
Dr Guo-Wei He (Hong Kong, China). Congratulations for
our elegant study. I have 2 questions.
Regarding the plasma concentration of magnesium, how did
ou decide your magnesium level of plasma concentration should
e increased to 1.5 to 2 times? How did you decide on this index?
Second, in your placebo group, do you also use the magnesium
ardioplegia? I believe if you use blood cardioplegia, it contains 8
o 10 mEq of magnesium that would be absorbed into the blood
lso. Therefore, the question is this: Did you measure the plasma
oncentration of magnesium in those placebo group patients as
ell to make a fair comparison?
Dr Bhudia. Thank you for your comments. The question about
ow much magnesium to give and what level to bring it up to was
ne we had to answer early on. Some animal studies have shown
hat a serum magnesium level of 3.6 mg · dL1, approximately 1.5
imes normal range in human subjects, is the neuroprotective dose.
hat is how we decided on 3.6 mg · dL1 to 4.8 mg · dL1. The
pper limit, 4.8 mg · dL1, was high, but not high enough to cause
ide effects.
Regarding whether we measured magnesium levels in the pla-
ebo group, the answer is yes. One of our graphs showed that theA
CDagnesium occurred during aortic clamping. The magnesium 2 curves of magnesium levels were significantly different.and Cardiovascular Surgery ● Volume 131, Number 4 861
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CDppendix E1. Details of Trial Design
ypothesis
eeping serum magnesium levels greater than 1½ times adult
ormal range during CPB and 24 hours thereafter in patients
ndergoing cardiac surgery has no neuroprotective effect.
rial Design
andomized, blinded, placebo-controlled, single-site clinical study
n which patients undergoing elective cardiac surgery were ran-
omized to have serum magnesium levels increased to 1½ to 2
imes normal level versus placebo. The trial included the following
nteractions with patients, interventions, and assessments:
1. Three to 4 days before surgery: consent, followed by neu-
rologic, neuropsychologic, and depressive assessment
2. Day of operation: randomization to treatment or placebo
3. Induction of anesthesia: intravenous bolus of magnesium
sulfate or placebo over 15 minutes, followed by infusion
over 24 hours
4. Off CPB: possible magnesium sulfate bolus of 1 g (surgeon
practice); this is given occasionally to prevent cardiac ar-
rhythmias, with the surgeon making the decision
5. 24 hours after surgery: magnesium sulfate or placebo dis-
continued
6. 24 hours after extubation: neurologic assessment
7. Extubation: neurologic assessment
8. 96 hours after surgery: neurologic assessment
9. 90 days after surgery: neuropsychologic and depressive
inventory assessment.
atient Population
atients were recruited from the 7-county Cleveland region if they
ere admitted to Cleveland Clinic for elective on-pump cardiac
urgery. Other patients from outside this region who were willing
o come back for 3-month assessment were also recruited.
nclusion Criteria
atients 18 years or older scheduled to undergo elective CABG,
alve surgery, or both, on CPB who consented for the trial.
xclusion Criteria
1. Preoperative atrial fibrillation.
2. Preoperative renal impairment, defined as plasma creatinine
level greater than 2.0 or on chronic renal dialysis.
3. Participation in another trial.
4. Inability to read, write, or comprehend English.
5. Refusal to consent.
In toto, other than refusal to consent, 29 patients were ex-
luded: 1 with diabetic retinopathy was unable to read, 1 was
nable to understand instructions, 2 discontinued the assessment
withdrew consent), 2 had a baseline assessment but then withdrew
onsent, 5 had baseline assessment but either had no operation or61.e1 The Journal of Thoracic and Cardiovascular Surgery ● Apxtensive than the one contemplated at the time of baseline as-
essment that did not meet inclusion criteria.
ample Size
eurologic decline or death from neurologic injury was antic-
pated to be 35% in the control group. Assuming this would be
0% in the treatment group, a 2-group test of independent
roportions, a type I error of 0.05, and a 2-tailed alternative, a
otal sample size of 300 would achieve at least 80% power to
etect this difference. This was augmented by 50 patients to
uard against overly optimistic anticipated differences and the
ossibility that not all consenting patients would complete all
ests.
agnesium Dose
agnesium dosing was derived from the knowledge that (1)
erum magnesium concentrations 1½ times normal (3.62
g · dL1) were associated with reduced histologic infarct vol-
me in ischemic injury animal models,E1 (2) concentrations 2 to 3
imes normal (4.2 mg · dL1 to 6.8 mg · dL1) with reduced
ccurrence of preeclamptic and eclamptic seizure,E2 and (3) con-
entrations 1½ to 2 times normal with important clinical benefit in
cute stroke.E3
eferences
1. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh
E. Neuroprotective effects of preischemia intraarterial magne-
ium sulfate in reversible focal cerebral ischemia. J Neurosurg.
996;85:117-24.
E2. Thurnau GR, Kemp DB. Cerebrospinal fluid levels of
agnesium in patients with preeclampsia after treatment with
ntravenous magnesium sulfate: a preliminary report. Am J Obstet
ynecol. 1997;158:1435-8.
E3. Muir KW, Lees KR. Dose optimization of intravenous
agnesium sulfate after acute stroke. Stroke. 1998;29:918-23.
ppendix E2. Analyses of Neuropsychologic and
epressive Inventory Scores
rincipal components analysis of preoperative test scores identi-
ed 4 components accounting for 72% of total variation: principal
omponent 1 for 42%, 2 for 13%, 3 for 9%, and 4 for 8%. These
components can be interpreted as follows (Table E3):
1. Weighted average of all tests except Beck Depression In-
ventory, second edition. A lower score signifies worse
performance.
2. Mainly represents average of 3 trials of the Hopkins Verbal
Learning Test scores. A lower score signifies worse perfor-
mance.
3. Represents Beck Depression Inventory, second edition. A
higher score signifies higher levels of depressive symptom-
atology.
4. Mainly represents the Boston Naming Test and Controlled
Oral Word Association Test (word fluency). A lower scorepercutaneous procedure, and 18 underwent an operation more signifies worse performance.ril 2006
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CDFigure E2. Unadjusted preoperative and 3-month follow-up neuropsychologic test scores presented for magnesium
and placebo groups. Top whisker, Maximum score; bottom whisker, minimum score; top line in box, 85th
percentile; middle line, median; bottom line, 15th percentile; , mean. A, Hopkins Verbal Learning Test (HVLT). B,
HVLT delayed recall. C, HVLT discrimination index. D, Controlled Oral Word Association Test (COWAT). E, Boston
Naming Test. F, Digit Symbol. G, Symbol Search. H, Grooved Pegboard, dominant hand (D). I, Grooved Pegboard,
nondominant hand (ND). J, Trail-Making Test Form A. K, Trail-Making Test Form B. L, Beck Depression Inventory
second edition.61.e3 The Journal of Thoracic and Cardiovascular Surgery ● April 2006
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A
CDABLE E1. Characteristics of patients who completed 3-month follow-up neuropsychologic study
haracteristic Magnesium group (n  132), No. (%) Placebo group (n  141), No. (%) P value
emography
Female 26 (20) 25 (18) .7
Age (y), mean  SD 62  12 63 13 .6
Body mass index (kg · m2) 29  5 29 6 .5
reoperative neurologic morbidity
CVA 1 (0.8) 2 (1) 1*
TIA 8 (6) 5 (4) .4*
Syncope 8 (6) 11 (8) .6
ardiac morbidity
Previous MI 53 (40) 45 (32) .2
Atrial fibrillation 4 (3) 3 (2) .7*
Previous cardiac operation 30 (23) 26 (18) .4
NYHA class .1
I 35 (27) 34 (24)
II 76 (58) 97 (69)
III 18 (14) 9 (6)
IV 3 (2) 1 (0.7)
Aortic regurgitation (moderate or greater) 37 (28) 31 (22) .2
Aortic stenosis (moderate or greater)† 26 (20) 42 (31) .04
Mitral regurgitation (moderate or greater)‡ 55 (42) 55 (39) .6
Mitral stenosis (moderate or greater)§ 1 (0.8) 4 (3) .4*
Coronary disease
LMT stenosis (50%) 20 (16) 23 (17) .9
LAD stenosis (70%)¶ 69 (55) 68 (50) .4
LCx stenosis (70%)¶ 56 (45) 50 (37) .2
RCA stenosis (70%) 58 (47) 68 (50) .6
Three-system disease 59 (47) 60 (44) .9
oncardiac comorbidity
Hypertension# 88 (67) 103 (74) .2
Diabetes mellitus 27 (20) 29 (21) .9
Peripheral vascular disease 61 (46) 47 (33) .03
Carotid disease 57 (43) 42 (30) .02
COPD 22 (17) 17 (12) .3
History of smoking 66 (50) 78 (55) .4
rocedure
Isolated CABG 53 (40) 49 (35) .4
CABG  valve procedure 33 (25) 42 (30) .4
Aortic valve repair 5 (4) 2 (1) .3*
Aortic valve replacement 41 (31) 58 (41) .08
Mitral valve repair 35 (27) 34 (24) .6
Mitral valve replacement 5 (4) 10 (7) .2
Tricuspid valve repair 2 (2) 6 (4) .3*
upport
Perfusion time (min) 91 36 91 35 .8
Ischemic time (min) 73 29 73 30 .9
D, Standard deviation; CVA, cerebrovascular accident; TIA, transient ischemic attack; MI, myocardial infarction; NYHA, New York Heart Association; LMT,
eft main trunk; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; COPD, chronic obstructive
ulmonary disease; CABG, coronary artery bypass grafting. *Fisher’s exact test. †Three unknown in magnesium group, 6 unknown in placebo group. ‡Two
nknown in magnesium group, 1 unknown in placebo group. §Two unknown in magnesium group, 4 unknown in placebo group. Eight unknown in
agnesium group, 4 unknown in placebo group. ¶Seven unknown in magnesium group, 4 unknown in placebo group. #One unknown in placebo group.The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 4 861.e4
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CDABLE E2. Characteristics of patients who completed 3-month neuropsychologic battery compared with patients who
id not
haracteristic Completed (n  273), No. (%) Not completed (n  77), No. (%)* P value
emography
Female 51 (19) 29 (38) .0005
Age (y), mean  SD 63  12 65 13 .05
Body mass index (kg · m2) 29  6 31 7 .1
reoperative neurologic morbidity
CVA 3 (1) 3 (4) .3†
TIA 13 (5) 7 (9) .1
Syncope 19 (7) 6 (8) .8
ardiac morbidity
Previous MI 98 (36) 33 (43) .3
Atrial fibrillation 7 (3) 0 (0) .4†
Previous cardiac operation 56 (21) 12 (16) .3
NYHA class .2
I 69 (25) 17 (22)
II 173 (63) 46 (60)
III 27 (10) 10 (13)
IV 4 (1) 4 (5)
Aortic regurgitation (moderate or greater) 68 (25) 20 (26) .8
Aortic stenosis (moderate or greater)‡ 68 (26) 25 (34) .2
Mitral regurgitation (moderate or greater)§ 110 (41) 31 (40) .9
Mitral stenosis (moderate or greater) 5 (2) 2 (3) .6†
Coronary disease
LMT stenosis (50%)¶ 43 (16) 7 (10) .1
LAD stenosis (70%)# 137 (52) 39 (52) .9
LCx stenosis (70%)# 106 (40) 34 (45) .4
RCA stenosis (70%)¶ 126 (48) 37 (49) .9
Three-system disease 112 (43) 32 (43) .9
oncardiac comorbidity
Hypertension** 191 (70) 55 (71) .8
Diabetes mellitus 56 (21) 20 (26) .3
Peripheral vascular disease 108 (40) 28 (36) .6
Carotid disease 99 (36) 24 (31) .4
COPD 39 (14) 14 (18) .4
History of smoking** 144 (53) 41 (54) .8
rocedure
Isolated CABG 102 (37) 26 (34) .6
CABG  valve procedure 75 (27) 23 (30) .7
Aortic valve repair 7 (3) 0 (0) .4†
Aortic valve replacement 99 (36) 31 (40) .5
Mitral valve repair 69 (25) 20 (26) .9
Mitral valve replacement 15 (5) 5 (6) 1†
Tricuspid valve repair 8 (3) 2 (3) 1†
upport
Perfusion time (min) 91 36 97 34 .08
Ischemic time (min) 73 30 78 28 .04
D, Standard deviation; CVA, cerebrovascular accident; TIA, transient ischemic attack; MI, myocardial infarction; NYHA, New York Heart Association; LMT,
eft main trunk; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary artery; COPD, chronic obstructive
ulmonary disease; CABG, coronary artery bypass grafting. *Patients who died were excluded. †Fisher’s exact test. ‡Nine unknown in completed group,
unknown in incomplete group. §Three unknown in completed group. Six unknown in completed group, 1 unknown in incomplete group. ¶Twelve unknown
n completed group, 2 unknown in incomplete group. #Eleven unknown in completed group, 2 unknown in incomplete group. **One unknown in completed
roup.61.e5 The Journal of Thoracic and Cardiovascular Surgery ● April 2006
T
d
T
H
C
B
D
S
G
T
B
P
T
p
o
T
H
C
B
D
S
G
T
B
*
Bhudia et al Surgery for Acquired Cardiovascular Disease
A
CDABLE E3. Principal components of neuropsychologic and
epression inventory tests
est PC #1 PC #2 PC #3 PC #4
opkins Verbal Learning
Test
Total of 3 trials 0.282 0.436
Delayed recall 0.272 0.484
Discrimination index 0.214 0.471
ontrolled Oral Word
Association Test
0.234 0.456
oston Naming Test 0.198 0.751
igit Symbol 0.361
ymbol Search 0.348
rooved Pegboard
Dominant hand 0.320
Nondominant hand 0.322
rail-Making Test
Form A 0.337
Form B 0.366
eck Depression Inventory,
second edition
— 0.720
C, Principal component.
ABLE E4. Neuropsychologic and depression inventory
erformance 3 months postoperatively compared with pre-
peratively in entire study population
est Performance at 3 mo* P value
opkins Verbal Learning Tests
Total of 3 trials Better .0001
Delayed recall Better .002
Discrimination index Better .004
ontrolled Oral Word
Association Test
No change .9
oston Naming Test Better .0001
igit Symbol No change .08
ymbol Search Better .05
rooved Pegboard
Dominant hand Better .0008
Nondominant hand Better .003
rail-Making Test
Form A No change .2
Form B Better .05
eck Depression Inventory,
second edition
Better .0001
TABLE E5. Factors associated with lower PC #1 score
Factor Coefficient  SD P value
Unadjusted
Lower preoperative PC #1 score 0.91 0.03 .0001
Magnesium group 0.019 0.14 .9
Adjusted
Lower preoperative PC #1 score 0.78 0.035 .0001
Magnesium group 0.067 0.12 .6
CVA 1.74 0.57 .003
History of TIA 0.57 0.30 .06
Older* 0.33 0.096 .0006
Diabetes 1.2  0.75 .1
Interaction: older patients with
diabetes†
0.42 0.20 .04
Higher BUN‡ 0.14 0.029 .0001
Note: Primary component #1 is a weighted average of all tests, except the
Beck Depression Inventory. PC, Principal component; SD, standard devi-
ation; CVA, cerebrovascular accident; TIA, transient ischemic attack; BUN,
blood urea nitrogen. *Exp(age/50), exponential transformation. †Exp(age/
50)  diabetes, interaction term. ‡Exp(BUN/20), exponential trans-
formation.
TABLE E6. Factors associated with lower PC #2 score
Factor Coefficient  SD P value
Unadjusted
Lower preoperative PC #2 score 0.67 0.05 .0001
Magnesium group 0.063 0.12 .6
Adjusted
Lower preoperative PC #2 score 0.64 0.05 .0001
Magnesium group 0.07 0.05 .6
Lower WRAT-3 reading score* 0.30 0.086 .0007
Left main trunk disease (70%
stenosis)
0.57 0.24 .02
Mitral valve repair 0.37 0.14 .01
Higher Canadian angina class 0.14 0.06 .03
More recent date of operation† 0.14 0.05 .008
Note: Principal component #2 is an average of all 3 Hopkins verbal learning
tests. PC, Principal component; SD, standard deviation; WRAT-3, Wide
Range Achievement Test, third edition. *Standardized (Z) score. †Exp(intervalCompared with preoperative performance. f
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CDABLE E7. Factors associated with higher PC #3 score
actor Coefficient  SD P value
nadjusted
Higher preoperative PC #3 score 0.56 0.05 .0001
Magnesium group 0.031 0.097 .8
djusted
Higher preoperative PC #3 score 0.59 0.05 .0001
Magnesium group 0.007 0.09 .9
Older* 0.15 0.058 .01
Preoperative ventricular
arrhythmia
0.30 0.16 .06
Severe mitral valve stenosis 0.19 0.08 .03
Shorter myocardial ischemic time† 0.21 0.12 .08
ote: Represents Beck Depression Inventory, second edition. PC, Prin-
ipal component; SD, standard deviation. *Exp(age/50), exponential
ransformation. †Myocardial ischemic time/70, inverse transformation.
ABLE E8. Factors associated with lower PC #4 score
actor Coefficient  SD P value
nadjusted
Lower preoperative PC #4 score 0.76 0.04 .0001
Magnesium group 0.05 0.08 .6
djusted
Lower preoperative PC #4 score* 8.2  0.49 .0001
Magnesium group 0.098 0.08 .8
Lower WRAT-3 reading score† 0.19 0.054 .0005
Lower BUN‡ 0.04 0.02 .02
No COPD 0.26 0.11 .02
ote: Mainly represents word fluency. PC, Principal component; SD, stan-
ard deviation; WRAT-3, Wide Range Achievement Test, third edition;
UN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease.
Ln(PC #4 score), logarithmic transformation †Standardized (Z) score.
Exp(BUN/20), exponential transformation.
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